Wave 80 to Unveil Latest Advances in High-Speed Microfluidics Technology at SemiCon China
Semiconductor manufacturing processes leveraged in production of unique fluidic actuator chips.
San Francisco, California, March 1, 2013—Dr. Daniel Laser, Wave 80’s Chief Executive Officer and President, will discuss major recent advances in the company’s bioassay technology as part of an invited talk at the upcoming Semicon China 2014 conference, the company announced today. The conference, to be held in Shanghai from March 18-20, 2013, is a leading international forum for new product releases and announcements in the semiconductor and solar power sectors.
Dr. Laser’s talk will highlight recent advances relating to Wave 80’s SCAFA technology. SCAFA microfluidic actuator chips are a key element of EOSCAPE next-generation molecular diagnostics testing system. Several of the chips are built into each EOSCAPE cartridge.
SCAFA chips pack incredible power into a tiny package. A single SCAFA—measuring a few millimeters on a side—can propel a fluid mass equivalent to many multiples of the chip’s own mass from one end of a reaction channel to the other in only seconds. Yet SCAFA chips consume less than one-hundredth of the electrical power input required by a typical microprocessor chip.
Dr. Laser’s presentation will highlight recent advances in SCAFA-enabled bioassay process optimization. With the latest SCAFA designs, two or more discrete fluid volumes—each containing one or more slow-diffusing species—can be fully reacted in approximately two centimeters of fluid conduit length. The minimum required fluid conduit length was previously five to 10 centimeters.
Dr. Laser, who received a Ph.D. in mechanical engineering from Stanford University, holds numerous patents on microfluidic actuators and other technologies with diverse applications in biotechnology, energy systems, telecommunications, and information technology.
About Wave 80
Wave 80 Biosciences develops next-generation molecular diagnostics instruments and consumables for human health conditions including HIV/AIDS, chlamydia, respiratory illness, hepatitis C, and certain cancers and autoimmune diseases. Distinguished by a novel one patient-one test usage model, best-in-class performance, and a superior value proposition, Wave 80’s pipeline products address unmet needs of diverse patient populations worldwide in the high-clinical-value molecular diagnostics segment of the clinical laboratory testing systems market.